Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Asia
Asia
Eisai files Leqembi in Korea, as US prospects firm up
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Flag link:
Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record
Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record
Fierce Biotech
Astellas
menopause
FDA
clinical trials
Asia
fezolinetant
hot flashes
Flag link:
Merck KGaA launches Asia startup scheme to locate next generation of partnerships
Merck KGaA launches Asia startup scheme to locate next generation of partnerships
Fierce Biotech
Asia
Merck KGaA
startups
funding
Flag link:
Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal
Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal
Endpoints
Bavarian Nordic
RSV
vaccines
Asia
Nuance Pharma
Flag link:
Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
Endpoints
Kiniksa Pharmaceuticals
Regeneron
Arcalyst
Huadong Medicine
Asia
mavrilimumab
Flag link:
Covid-19 vaccine maker Moderna to set up subsidiary in Singapore as it boosts regional presence
Covid-19 vaccine maker Moderna to set up subsidiary in Singapore as it boosts regional presence
Today Online, Singapore
Moderna Therapeutics
Singapore
Asia
vaccines
COVID-19
Flag link:
2 Medtech Giants Are Working to Enhance Cardiac Care in Southeast Asia
2 Medtech Giants Are Working to Enhance Cardiac Care in Southeast Asia
Medical Devices and Diagnostics Industry
devices
Medtech
Asia
GE Healthcare
Boston Scientific
interventional cardiology
Flag link:
Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar
Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar
Pharmaceutical Business Review
Prestige BioPharma
Dr Reddy's
trastuzumab
biosimilars
Latin American
Asia
Flag link:
Is Vaccine Latecomer Inovio Making a Comeback?
Is Vaccine Latecomer Inovio Making a Comeback?
Motley Fool
Inovio
vaccines
COVID-19
clinical trials
Africa
Latin America
Asia
Flag link:
Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia
Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia
Fierce Biotech
LianBio
Landos Biopharma
IPOs
ulcerative colitis
Crohn's Disease
China
Asia
Flag link:
Samsung Biologics and AstraZeneca launch strategic manufacturing partnership
Samsung Biologics and AstraZeneca launch strategic manufacturing partnership
Biopharma Reporter
Samsung BioLogics
AstraZeneca
Asia
biologics
drug manufacturing
Flag link:
Amgen Is Making 3 Big Bets -- Will They Pay Off for Investors?
Amgen Is Making 3 Big Bets -- Will They Pay Off for Investors?
Motley Fool
Amgen
earnings
M&A
Asia
Flag link:
With Immunomedics ADC deal, Everest bolsters cancer pipeline
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
Flag link:
Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut
Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut
South China Morning Post
Asia
Hong Kong
Ascletis
Flag link:
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
CP Wire
AB928
Arcus Biosciences
Taiho Pharmaceutical
oncology
Asia
Japan
Flag link:
With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure
With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure
Endpoints
Aquinox Pharmaceuticals
Astellas
rosiptor
Asia
clinical trials
Interstitial Cystitis
Flag link:
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
Endpoints
SAGE Therapeutics
SAGE-217
Asia
Shionogi
depression
Flag link:
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
Endpoints
China
Asia
Oncologie
Flag link:
Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug
Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug
Fierce Biotech
Astellas
Aquinox Pharmaceuticals
SHIP1 activator
Japan
Asia
rosiptor
Flag link:
Merck KGaA injects $47M into Asian manufacturing efforts
Merck KGaA injects $47M into Asian manufacturing efforts
Biopharma Dive
Merck KGaA
drug manufacturing
Asia
India
South Korea
Flag link:
Pages
1
2
3
4
next ›
last »